N
← Back to Search
Sponsored

Accelerate Your Clinical Trial Recruitment

Reach thousands of high-intent patients matching your specific inclusion criteria.

Start Campaign
RECRUITING Phase 4 ClinicalTrials.gov

Combination Antibiotic Therapy for Staphylococcus Aureus Bacteremia

Sponsor: Intermountain Health Care, Inc. • ClinicalTrials.gov ID: NCT07376889

Registry updated: 2026-09-25
Ad

Recruiting for Similar Conditions?

Sponsors are looking for patients like you. See if you qualify for compensated research studies.

Check Eligibility →

Description

The purpose of this study is to see if, in selected patients with a serious bacterial infection of the bloodstream, treating the bacterial infection with a combination of antibiotics is more effective than treating the infection with a single antibiotic. Participants must have blood cultures which are positive for a certain type of bacteria.

Interventions

  • Antibiotic Monotherapy (AM) for patients with methicillin-sensitive S. aureus bacteremia (MSSAB) (Drug)
    Intravenous anti-staphylococcal beta-lactam, either cefazolin or nafcillin, per the discretion of the treating physician.
  • Antibiotic Monotherapy (AM) for patients with methicillin-resistant S. aureus bacteremia (MRSAB) (Drug)
    Vancomycin or daptomycin, per discretion of the treating physician
  • Combination Antibiotic Therapy (CAT) for patients with methicillin-sensitive S. aureus bacteremia (MSSAB) (Drug)
    Patients with methicillin-sensitive S. aureus bacteremia (MSSAB) and no contraindications will receive an anti-staphylococcal beta-lactam, either cefazolin or nafcillin, plus ertapenem
  • Combination Antibiotic Therapy (CAT) for patients with methicillin-resistant S. aureus bacteremia (MRSAB) (Drug)
    Daptomycin plus ceftaroline

Eligibility criteria

Inclusion Criteria: * Age ≥18 years * Alive and admitted to an Intermountain Health (IH) hospital acute care unit at enrollment * Initial positive blood culture with either methicillin-resistant Staphylococcus aureus (MRSA) or methicillin-susceptible Staphylococcus aureus (MSSA), collected: 1. on or during the index admission to an IH hospital, or 2. in an ambulatory setting (laboratory, clinic or emergency department) within 48 hours of the index admission, or 3. at a non-IH network hospital within 24 hours of subsequent transfer to an IH hospital Exclusion Criteria: * Patient requests that patient health data not be included in the analysis

Conditions

Staphylococcus Aureus Bacteremia

Locations

  • Platte Valley Hospital — Brighton, Colorado, United States
  • Saint Joseph Hospital — Denver, Colorado, United States
  • St. Mary's Regional Hospital — Grand Junction, Colorado, United States
  • Good Samaritan Hospital — Lafayette, Colorado, United States
  • Lutheran Medical Center — Wheat Ridge, Colorado, United States
  • St. Vincent Regional Hospital — Billings, Montana, United States
  • St. James Hospital — Butte, Montana, United States
  • Holy Rosary Hospital — Miles City, Montana, United States
  • Intermountain Medical Center — Murray, Utah, United States
  • McKay-Dee Hospital — Ogden, Utah, United States
  • Utah Valley Hospital — Provo, Utah, United States
  • LDS Hospital — Salt Lake City, Utah, United States
  • St. George Regional Hospital — St. George, Utah, United States
Sponsored

Partner with Nurenyx

Showcase your study to thousands of motivated patients matching your criteria.

Learn More

Official Source

Data sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

View Official Record